In Waltham, Massachusetts, on April 3, 2026, Spyre Therapeutics, Inc. (NASDAQ: SYRE) disclosed that the independent Compensation Committee of the Board of Directors sanctioned the allocation of stock options for the purchase of a total of 70,200 common stock shares of Spyre. These options were granted to five non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, recently amended. The approval for these stock options was granted on April 1, 2026. The award was significant for each employee as it played a key role in their decision to join Spyre, meeting the criteria set by Nasdaq Listing Rule 5635(c)(4).